Terns Pharmaceuticals Inc TERN

$52.95 +0.02 (0.04%)

Valuation

Market cap: 6,116,838,000
Revenue TTM: $0
Net income TTM: $-96,210,000
PE ratio: 0.00
Forward PE: —
Profit margin: 0.00%
Debt to equity: 0.00

Trading

Volume: 6,347,000
Avg volume: 6,722,514
Day's range: $52.94 – $52.98
Shares out: 115,521,000
Stochastic %K: 85%
Beta: -0.37
Analysts: Hold
Price target: $53.00

Price

Company profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 525 5535
Website: https://www.ternspharma.com
Address: 1065 East Hillsdale Boulevard, Suite 100, Foster City, United States

Latest news

No headlines yet.

Stocktwits

SellasgpsCurativeBAT11 Sep 30, 5:25 PM

$CDTX $MRK $SLS $TERN Big Pharmaceuticals due to $380 Billion patent cliff averaging 2 deals a week so far this year. Sellas Next up! ✌️🙏❤️‍🩹

0 replies

SellasgpsCurativeBAT11 Sep 30, 12:16 AM

$SLS $MRK $CDTX $TERN The SciBrunch deal is Merck's latest move to bolster its pipeline as it braces for the loss of patent protection for its blockbuster cancer drug Keytruda in 2028. Merck in May completed its nearly $6 billion acquisition of cancer biotech Terns Pharmaceuticals and its promising leukemia treatment, and the company in January wrapped up its $9.2 billion purchase of Cidara Therapeutics, a biotech making a new flu prevention drug. Biotechnology sector M&A is extremely hot right now due to $380 Million in patent cliffs. Big pharmaceuticals are buying up small to mid stage up front for massive premiums or Partnership deals. $SLS will be Acquired for $30- $40 Billion making it the biggest biotech deal of 2026. Mark this post ! ✌️🙏❤️‍🩹

0 replies

TradeSun Sep 20, 8:36 PM

$ALT $TERN What You Don’t See Before a Buyout Dec 8, 2025 — TERN-701 data update Dec 11 — $747.5M offering closes Dec 23 — First acquisition proposal from Party C Dec 24 — Board forms Transaction Committee — not publicly known at the time Jan 2026 — Multiple potential buyers involved, including Parties A, B, C, D, E and Merck Mar 24 — Merck merger agreement signed at $53/share

0 replies

TradeSun Sep 20, 6:26 PM

$ALT Thanks @Turribull $TERN — Nothing new, but extremely remarkable: • Dec 11, 2025: Closed a massive $747.5M public offering only 3.5 months before the buyout announcement!!! • Mar 25, 2026: Merck announces acquisition of Terns for $53/share and Short interest: • Mar 2025: 5.77M • Sep 2025: 8.23M • Dec 2025: 15.45M • Feb 2026: 16.62–18.61M • Mar 13, 2026: 18.19M again👇wow!

0 replies

OMillionaires Sep 11, 8:42 PM

$CRBP - CB1 vs. GLP1 but my $TERN was bought out for $6.7 billion $CRBP stock price/valuation: At $25 a share $466 mil company At $50 a share $933 mil company at $100 a share $1.867 billion At $150 a share $2.8 billion

0 replies

et1000 Sep 9, 10:41 PM

$TERN lets go 100 ?

0 replies

55X_ROI_Q1_2026 Sep 8, 12:43 AM

$SLS $TERN $GILD once again to drive this point home - SLS009 Phase 2 Expansion Data Published at ASH in DEC for AML-MR patients - the most dire AML Prognosis - WAS BETTER than the $FTSV MAGRO PH1B AML-MR Data published at ASH, that $GILD Bought for $4.9B ... JUST THE SECONDARY SLS009 ASSET is ALREADY WORTH 2x 3x the current SHORT Rigged Market Cap --- right now --- With PIVOTAL, RANDOMIZED Dual ARM - FDA GREEN Light Data Incoming NEXT Quarter - in Q4. List of FDA Approved drugs based on P1/2 Data: 009 is next.

0 replies

55X_ROI_Q1_2026 Sep 7, 9:59 PM

$SLS 2 Quick Points: 1.) SLS 009 is already worth 2x 3x the current Short Rigged $2.7B Mcap - based on the $TERN $FTSV direct comps. $GILD bought Magro for $4.9B based on PH1b AML-MR Data that was NOT As good as the SLS009 PH2 AML-MR Data PUBLISHED At ASH in DEC. and the SLS009 ONGOING - Dual ARM, Randomized - PIVOTAL Trial w FDA Green light data DUE NEXT Q - in Q4 - at the FDA Request. 2.) Gps is Golden -- you may not know, but smart money does - and the ONLY REAL Question is - WHAT IS GPS WORTH ??? https://www.reddit.com/r/sellasLifescience/s/FCS5ujRm9T

0 replies